Urokinase-type plasminogen activator receptor: a beacon of malignancy?


Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies.

  • Clauss A
  • Drapkin R
  • Skates S
PubMed ID
Appears In
Clin Cancer Res, 2008, 14 (18)